Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.43 |
| ▸ | CDK2 | P24941 | 12/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305310 | 0.84 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1GSK3B | |
| SCHEMBL3303806 | 0.82 | HTR2A (0.43) | CHEK1CCNA2CDK2CCNA1JAK3 | |
| SCHEMBL3304442 | 0.81 | PTK2 (0.43) | CHEK1CCNA2CDK2CCNA1JAK3 | |
| SCHEMBL2144923 | 0.77 | CHEK1 (0.46) | CHEK1CCNA2CDK2CCNA1ADORA2A | |
| SCHEMBL3303916 | 0.71 | IDH2 (0.47) | CDK2PRKCZ | |
| SCHEMBL3297635 | 0.71 | IDH2 (0.47) | CDK2PRKCZ | |
| SCHEMBL2144863 | 0.70 | KDM4E (0.37) | CHEK1CCNA2CDK2CCNA1ADORA2A | |
| SCHEMBL13998548 | 0.67 | GSK3B (0.73) | CHEK1CCNA2CDK2CCNA1GSK3B | |
| SCHEMBL3303802 | 0.66 | HTR2A (0.43) | CHEK1CCNA2CDK2CCNA1JAK1 | |
| SCHEMBL3304440 | 0.65 | PTK2 (0.39) | CHEK1CCNA2CDK2CCNA1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CHEK1 44/4885CCNA2 587/4885CDK2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.